Drugs.com - Clinical Trials

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being...

Feb 9, 2025 - 21:44
 0
Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease
TITUSVILLE, N.J., January 8, 2025 -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being...
Read More

Tags:

Previous Article

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized My...

Next Article

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obst...

Related Posts

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, Receives US FDA Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

GSK’s B7-H3-Targeted Antibody-Drug Conjugate, GSK’227, ...

Feb 9, 2025  0

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Therapeutics Announces Positive ATH434 Phase 2...

Feb 9, 2025  0

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Announces Use of Tegoprubart as ...

Feb 9, 2025  0